Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Study reveals single copy of protective genetic variant delays early Alzheimer’s onset

Approximately 900,000 people in the UK are affected by dementia and Alzheimer’s is the most common form

- PMLiVE

Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

- PMLiVE

Beyond volume metrics: towards meaningful impact measurement for digital HCP engagement

By Matthew Hellyer

- PMLiVE

Eyes on the horizon: six (and a half) predictions for the future of healthcare communications

By Zoë van Helmond and Leyna Prince

Amiculum

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

The Communiqué Awards announces PAPYRUS as 2024 charity partner

PAPYRUS Prevention of Young Suicide aims to shatter the stigma that still surrounds suicide

- PMLiVE

Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

- PMLiVE

Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

- PMLiVE

Study suggests enlarged prostate drugs could protect against dementia with Lewy bodies

The second most common form of dementia affects one in every 1,000 people each year

- PMLiVE

Words aside, ESG’s role is non-negotiable

By Arabella Moore

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links